Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STRATA Skin Sciences Inc (SSKN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SSKN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9
1 Year Target Price $9
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.92% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.39M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 2 | Beta 0.71 | 52 Weeks Range 2.10 - 3.80 | Updated Date 06/30/2025 |
52 Weeks Range 2.10 - 3.80 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.22% | Operating Margin (TTM) -29.58% |
Management Effectiveness
Return on Assets (TTM) -7.6% | Return on Equity (TTM) -151.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19270112 | Price to Sales(TTM) 0.28 |
Enterprise Value 19270112 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 0.57 | Enterprise Value to EBITDA -7008.83 | Shares Outstanding 4171160 | Shares Floating 1172430 |
Shares Outstanding 4171160 | Shares Floating 1172430 | ||
Percent Insiders 5.48 | Percent Institutions 64.08 |
Analyst Ratings
Rating 2 | Target Price 9 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
STRATA Skin Sciences Inc
Company Overview
History and Background
STRATA Skin Sciences, Inc. (formerly PhotoMedex, Inc.) was founded in 1989. It is a medical technology company focused on developing and commercializing products for the treatment of dermatological conditions. It has evolved from a laser manufacturer to a company focused on capital equipment for dermatologists.
Core Business Areas
- XTRAC Segment: XTRAC is an excimer laser system used for the treatment of psoriasis, vitiligo, and atopic dermatitis. This represents the core revenue stream of the company.
- Pharos Segment: Pharos is a non-laser based narrowband UVB system used for the treatment of psoriasis, vitiligo, and atopic dermatitis.
Leadership and Structure
The leadership team includes management and a board of directors. The organizational structure is typical of a small-cap medical device company, with departments focused on sales, marketing, R&D, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- XTRAC Laser System: The XTRAC excimer laser system is the company's flagship product, used for targeted phototherapy treatment of psoriasis, vitiligo and eczema. Market share data is not readily available as a specific figure, but the company is a significant player in the targeted phototherapy market. Competitors include Daavlin and Waldmann.
- Pharos Excimer Laser: The Pharos excimer laser provides treatment for multiple skin diseases and conditions. Market share data is not readily available as a specific figure, but the company is a significant player in the targeted phototherapy market. Competitors include Daavlin and Waldmann.
Market Dynamics
Industry Overview
The dermatology device market is driven by the prevalence of skin conditions like psoriasis, vitiligo, and eczema. The market includes laser and light-based therapies, topical treatments, and systemic medications. Aging population and awareness of skin aesthetics are the key drivers for this market.
Positioning
STRATA Skin Sciences is positioned as a key player in the targeted phototherapy segment. Its competitive advantage lies in its established XTRAC brand name and its focus on dermatological conditions treatable with laser and light-based therapies.
Total Addressable Market (TAM)
The global dermatology devices market is projected to reach billions of dollars, with targeted phototherapy representing a segment of this market. STRATA's positioning in this segment gives it access to a portion of the overall TAM. TAM estimated ~$20B in 2024.
Upturn SWOT Analysis
Strengths
- Established XTRAC brand name
- Focus on targeted phototherapy
- Specialized sales and service network
- Proprietary technology
Weaknesses
- Small market capitalization
- Limited financial resources compared to larger competitors
- Dependence on a few key products
- Fluctuations in product sales.
Opportunities
- Expansion into new geographic markets
- Development of new applications for existing technologies
- Acquisition of complementary technologies or products
- Strategic partnerships with dermatology clinics and healthcare systems
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- Daavlin
- Waldmann
- Ra Medical Systems (RMED)
Competitive Landscape
STRATA Skin Sciences competes with larger medical device companies and smaller specialized players. Its advantages include its established brand name and focus on targeted phototherapy. Disadvantages include its small size and limited financial resources.
Major Acquisitions
Theraclear
- Year: 2014
- Acquisition Price (USD millions): 4.5
- Strategic Rationale: Expanded its product offerings in the aesthetic dermatology market
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by sales of the XTRAC system and related consumables. Growth rates have fluctuated.
Future Projections: Analyst estimates vary. Future growth will likely depend on successful commercialization of new products and expansion into new markets.
Recent Initiatives: Recent initiatives include product improvements, marketing campaigns, and partnerships with dermatology clinics.
Summary
STRATA Skin Sciences is a key player in the targeted phototherapy market. The company benefits from its well-known XTRAC brand, however, faces challenges due to its small size and competition from larger medical device companies. Future growth depends on commercializing new products and geographic expansion. Fluctuations in sales and profitability should be closely monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Accuracy is not guaranteed. Financial data is based on estimates and may vary from actual results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STRATA Skin Sciences Inc
Exchange NASDAQ | Headquaters Horsham, PA, United States | ||
IPO Launch date 2005-10-28 | President, CEO & Vice-Chairman Dr. Dolev Rafaeli Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 106 | |
Full time employees 106 | |||
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, and other skin conditions; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.